iRadimed Corporation (NASDAQ:IRMD) Shares Sold by Rhumbline Advisers

Rhumbline Advisers decreased its position in shares of iRadimed Corporation (NASDAQ:IRMD - Free Report) by 28.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,703 shares of the medical equipment provider's stock after selling 5,549 shares during the quarter. Rhumbline Advisers owned about 0.11% of iRadimed worth $719,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of IRMD. Vanguard Group Inc. raised its stake in shares of iRadimed by 4.4% during the fourth quarter. Vanguard Group Inc. now owns 536,811 shares of the medical equipment provider's stock valued at $29,525,000 after purchasing an additional 22,762 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of iRadimed by 3.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 227,257 shares of the medical equipment provider's stock valued at $12,499,000 after buying an additional 7,606 shares in the last quarter. Geode Capital Management LLC lifted its holdings in iRadimed by 17.9% in the 4th quarter. Geode Capital Management LLC now owns 222,772 shares of the medical equipment provider's stock worth $12,255,000 after purchasing an additional 33,879 shares during the last quarter. Northern Trust Corp lifted its holdings in iRadimed by 7.3% in the 4th quarter. Northern Trust Corp now owns 143,069 shares of the medical equipment provider's stock worth $7,869,000 after purchasing an additional 9,722 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in iRadimed by 94.1% in the 4th quarter. Bank of New York Mellon Corp now owns 100,108 shares of the medical equipment provider's stock worth $5,506,000 after purchasing an additional 48,534 shares during the last quarter. Institutional investors and hedge funds own 92.34% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded iRadimed from a "buy" rating to a "strong-buy" rating in a report on Tuesday, May 6th.

iRadimed Trading Down 0.4%

Shares of NASDAQ IRMD opened at $58.24 on Friday. The business has a fifty day simple moving average of $54.75 and a 200 day simple moving average of $55.05. The firm has a market capitalization of $740.81 million, a price-to-earnings ratio of 37.57 and a beta of 0.92. iRadimed Corporation has a one year low of $42.34 and a one year high of $63.29.

iRadimed Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, May 30th. Shareholders of record on Tuesday, May 20th were given a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend was Tuesday, May 20th. iRadimed's dividend payout ratio (DPR) is 43.87%.

iRadimed Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Want to see what other hedge funds are holding IRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iRadimed Corporation (NASDAQ:IRMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.